50
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation

, , , , , , , , , , , & show all
Pages 1409-1414 | Published online: 01 Jul 2009

  • Kaplan, ME., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D. and Wasserman, L.R. (1986) "Long-term management of polycythemia vera with hydroxyurea: a progress report", Senun. Hematol, 23, 167-171.
  • Murphy, S., Peterson, P., Hand, H. and Laszlo, J. (1997) "Experience of the polycythernia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment", Semin, Hematol, 34, 29-39.
  • Gruppo Italiano Studio Policitemial(1995) "Polycythemia vera: the natural history of 1213 patients followed for 20 years". Ann. Intern. Med, 123, 656-664.
  • Anagrelide Study Group(1992) "Anagrelide. a therapy for thrombocythcmic states: experience in 577 patients". Am. J. Med. 92, 69-76.
  • Reilly, J.T., Vellenga, E. and De Wolff, J.T. (1996) "Interferon treatment in polycythaemia vera", Leuk. Lymph. 22(Suppl. 1). 143-148. [Review].
  • Lengfelder, E., Gnesshammer, M. and Hehlmann, R. (1996) "Interferon-alpha in the treatment of essential thrombocythemia". Leuk. Lymph, 22(Suppl. 1), 135-142.
  • Tefferi, A. and Silverstein, M.N. (1994) "Recombinant human crythropoictin therapy in patients with myelofibrosis with myeloid metaplasia", Br. J, Haematol, 86, 893. [Letter].
  • Besa, E.C., Nowell, P.C., Geller, N.L. and Gardner, F.H. (1982) "Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival", Cancer 49, 308-313.
  • Silverstein, M.N. (1975) Agnogenic Myeloid Metaplasia (Publishing Sciences Group. Acton, MA). pp 1-126.
  • Tefferi, A., Mesa, R.A., Nagorney. D.M., Schroeder. G. and Silverstein, M.N. (2000) "Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients". Blood 95, 2226-2233.
  • Jurado, M., Deeg, H.J., Gooley, T., Anasetti, C., Chauncey, T., Flowers, M.E.D., Myerson, D., Storb, R. and Appelbaum, F.R. (2001) "Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia", Br. J. Haematol, 112, 392-396.
  • Sultan, C. (1991) In: Sultan, C. Scoazec, J.Y. and Imbert, M., eds. Histopathologie De La Moelle Osseuse: Indications Et Interpretation De La Biopsie Médullaire (Masson. Paris), pp 1 194.
  • Bennett, J.M., Catovsky, D., Daniel M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. and Sultan, C. (1985) "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group". Ann. Intern. Med. 103, 626-629.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton. D.A.G., Uralnick, H.R. and Sultan. C. (1982) "The FrcnehAmerican-British (FAB) co-operative group proposals for the classification of the myelodysplastic syndromes", Br. J, Haematol. 51, 189-199.
  • Slattery, J.T., CIift, R.A., Buckner, C.D., Radich, J., Storer, B. Bensinger, W.I., Soll. E., Anasetti, C., Bowden, R., Bryant, E., Chauneey, T., Deeg, H.J., Doney, K.C., Flowers, M., Gooley, T., Hansen, J.A., Martin, P.J., McDonald, G.B., Nash, R., Petersdorf. E.W., Sunders, J.E., Schoch, G., Stewart, P., Storb, R., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P. and Appelbaum, F.R. (1997) "Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation". Blood 89, 3055-3060.
  • McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandinuier. B.M., Molina, A.J., Maloney, D.G., Chauncey, T.K., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich. J., Wagner, J.L., Minor. S. Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E.D., Georges, G.E, Grumet, F.C., Kiem, H-P., Torok-Storb, B., Yu. C. Blume, K.G. and Storb, R.F. (2001) "Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects", Blood 97, 3390-3400.
  • Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V. Hansen, J., Hill, R., Lum, L., Martin, P., McGuffin, R., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., Yee, G. and Thomas. E.D (1986) "Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia", New Engl, J. Med. 314, 729-735.
  • Deeg, H.J., Lin, D., Leisenring, W., Boeekh, M., Anasetti, C., Appelbaum, F.R., Chauncey, T.R., Doney, K., Flowers, M., Martin. P., Nash, R., Schoch, G, Sullivan, K.M., Witherspoon, R.P. and Storh, R. (1997) "Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial". Blood 89, 3880-3887.
  • Deeg, H.J. and Yamaguchi, M. (2000) "Acute graft-versus-host disease". In: Atkinson. K., ed. Clinical Bone Marrow and Blood Stem Cell Transplantation (Cambridge University Press. Cainbridge. UK). pp 681-699.
  • Sullivan, K.M., Shulman, H.M., Storh, R., Weiden, P.L., Witherspoon, R.P., McDonald, G.B., Schubert, M.M., Atkinson, K. and Thomas E.D. (1981) "Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression". Blood 57, 267-276.
  • Kaplan, E.L. and Meter, P. (1958) "Nonparamrtric estimation from incomplete observations", J. Am. Stat. Assoc. 53, 457-481.
  • Stobart, K. and Rogers. P.C.J (1994) "Allogeneic bone marrow transplantation for an adolescent with polycythemia vera", Bone Marrow Transplant. 13, 337-339.
  • de Revel, T., Giraudier, S., Nedellec, G., Joussemet, M., Bourin, P., Schill, H. Gaillard, J.F and Auzanneau, G. (1995) "Allogeneic bone marrow transplantation for postpolycythemic myeloid metaplasia with myelofibrosis: a case report". Bone Marrow Transplant 16, 187-189.
  • Anderson, J.E., Sale, G., Appelbaum, F.R., Chauncey, T.R. and Storb, R. (1997) "Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythacmia vera or essential thrombocytosis". Br. J. Haematol, 98, 1010-1016.
  • International Collaboration for Transplantation in Agnogenic Myeloid Metaplasia Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka. D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton. L., CazalsHatem, D., Sale, G., De Witte, T. Deeg, H.J. and Gluckman, E. (1999) "Allogcneic stem cell transplantation for agnogenic mycloid metaplasia: A European group for blood and marrow transplantation. Société Française de Greffe de Moelle. Gruppo Italiano per il Trapianto del Midollo Ossco, and Fred Hutchinson Cancer Research Center collaborative study", Blood 93, 2831-2838.
  • Slavin, S., Nagler. A., Napurstek, H., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel. S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. and Or. R. (1998) "Nomnyeloablative stem cell transplantation and cell therapy as an alternative to conventional hone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases". Blood 91, 756-763.
  • Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondôn, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C. Komblau, S., Körbling, M., Keating, M., Kantarjian, H. and Champlin, R. (1997) "Engraftment of allogencic hematopoictic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy", Bloodd 89, 4531-4536.
  • Bomhauser, M., Thiede, C., Platzbecker, U. Jenke, A., Helwig, A., Plettig, R., Fretberg-Richter, J., Rollig, C., Geissler, G., Lutterbeck. K., Oelschlagel, U. and Ehninger, G. (2001) "Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients". Clin. Cancer Res. 7. 2254 2262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.